This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Eagle Pharmaceuticals (EGRX) Beats Q4 Earnings Estimates
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 323.26% and -0.32%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
TEVA Stock Declines Despite Q4 Earnings and Sales Beat
by Zacks Equity Research
TEVA beats on fourth-quarter earnings and sales. It issues its financial guidance for 2021. Stock down.
TEVA Posts In-Line Q3 Earnings, Lowers Sales View, Stock Down
by Zacks Equity Research
TEVA's earnings match estimates while sales miss the same for third-quarter 2020. It lowers its previously issued sales guidance for 2020. Stock down.
Eagle Pharmaceuticals (EGRX) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 303.45% and 7.81%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for October 15th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 307.14% and 11.95%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Teva (TEVA) Q2 Earnings Top, Stock Up Despite Coronavirus Woes
by Zacks Equity Research
Teva (TEVA) beats second-quarter estimates for earnings while missing the same for sales. It maintains its previously issued guidance for 2020. Stock up.
Eagle Pharmaceuticals (EGRX) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 78.72% and -3.63%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Teva (TEVA) Q1 Earnings Top, Coronavirus-Led Buying Aids Sales
by Zacks Equity Research
Teva (TEVA) beats estimates for earnings and sales in first-quarter 2020. It maintains previously issued guidance for 2020. Stock up.
Why Eagle Pharmaceuticals (EGRX) Might Surprise This Earnings Season
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Cardinal Health (CAH) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter performance is likely to reflect solid performance in Pharmaceutical segment.
3 Medical Product Stocks Set to Beat This Earnings Season
by Trina Mukherjee
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on several factors.
Earnings Preview: Eagle Pharmaceuticals (EGRX) Q1 Earnings Expected to Decline
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eagle Pharmaceuticals (EGRX) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 37.14% and 8.45%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Eagle Pharmaceuticals (EGRX) Q4 Earnings Expected to Decline
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teva (TEVA) Q4 Earnings In Line, Stock Up as Sales Stabilize
by Zacks Equity Research
Teva Pharmaceutical (TEVA) earnings match estimates but sales beat. Shares rise 9%.
Tyme Initiates Dosing in Pivotal Pancreatic Cancer Study
by Zacks Equity Research
Tyme (TYME) is evaluating its lead cancer candidate, SM-88, as third-line treatment for metastatic pancreatic cancer in a pivotal study.
Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up
by Zacks Equity Research
Tyme's (TYME) shares rise as the company inks deal with Eagle Pharmaceuticals to co-promote its investigational cancer metabolism-based therapy, oral SM-88, in the United States.
Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -16.13% and -5.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Eagle Pharmaceuticals (EGRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Eagle Pharmaceuticals (EGRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for October 17th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Zacks.com featured highlights include: Garmin, Eagle Pharmaceuticals, BMC Stock, SeaWorld and Zumiez
by Zacks Equity Research
Zacks.com featured highlights include: Garmin, Eagle Pharmaceuticals, BMC Stock, SeaWorld and Zumiez
5 Momentum Picks Screened on Driehaus Strategy
by Nitish Marwah
Richard Herman Driehaus used the "buy high and sell higher" rule to create an investment approach.
Insulet (PODD) Catches Eye: Stock Jumps 8.9%
by Zacks Equity Research
Insulet (PODD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.